HUDDINGE, Sweden, Dec. 20, 2002 (PRIMEZONE) -- The Medivir (Stockholm:MVIRb) Board has appointed Professor Bo Oberg, Ph.D., as acting CEO as of January 1, 2003. The process to appoint a permanent CEO continues.
Contacts;
Anders Vedin, Chairman of the Board mobile +46 708 761 570 Bo Oberg, entering CEO phone +46 8 608 31 00 Rein Piir, CFO and IR phone +46 8 608 31 23 or mobile +46 708 53 72 92
The Medivir Group
Medivir is an innovative and specialized research company active in the pharmaceuticals sphere, located in Cambridge, U.K., and Huddinge, Sweden. Medivir's research focuses on the development of new pharmaceutical compounds as inhibitors of target enzymes with protease or polymerase activity.
The group comprises Medivir AB, the subsidiaries Medivir U.K. Ltd. and CCS AB, plus second-tier subsidiaries CCS (U.K.) Ltd. and Nordic Care Sweden AB. Medivir has been listed on the Stockholm Stock Exchange since 1996.
The research portfolio includes projects against HIV, jaundice, shingles, cold sores, osteoporosis, rheumatoid arthritis, asthma, multiple sclerosis and organ/graft rejection. Medivir has four projects in clinical development. Of these, two are moving towards Phase III trials after having completed Phase II trials. One is in Phase I and one is in Phase II. Medivir's pre-clinical research encompasses a number of projects, of which one is on its way towards and two are in the lead optimization phase and one is in the late pre-clinical development stage. A further ten activities are in the explorative stage.
For more information about Medivir, visit the company's Website at www.medivir.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
www.waymaker.net/bitonline/2002/12/20/20021220BIT00940/wkr0001.doc www.waymaker.net/bitonline/2002/12/20/20021220BIT00940/wkr0002.pdf